Related references
Note: Only part of the references are listed.A kit to prepare In-111-DTPA-trastuzumab (Herceptin) Fab fragments injection under GMP conditions for imaging or radioimmunoguided surgery of HER2-positive breast cancer
Deborah A. Scollard et al.
NUCLEAR MEDICINE AND BIOLOGY (2011)
Imaging cancer using PET - the effect of the bifunctional chelator on the biodistribution of a Cu-64-labeled antibody
Jason L. J. Dearling et al.
NUCLEAR MEDICINE AND BIOLOGY (2011)
In vitro and in vivo pre-clinical analysis of a F(ab')(2) fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers
Karen J. Wong et al.
EJNMMI RESEARCH (2011)
Comparison of 18F PET and 99mTc SPECT Imaging in Phantoms and in Tumored Mice
Dengfeng Cheng et al.
BIOCONJUGATE CHEMISTRY (2010)
Changes of HER2 Status in Circulating Tumor Cells Compared With the Primary Tumor During Treatment for Advanced Breast Cancer
Elisabetta Munzone et al.
CLINICAL BREAST CANCER (2010)
Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer
E. C. Dijkers et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Synthesis, characterization and biological evaluation of In(III) complexes anchored by DOTA-like chelators bearing a quinazoline moiety
Raquel Garcia et al.
METALLOMICS (2010)
Associations between the uptake of In-111-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts
Kristin McLarty et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2009)
Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with 64Cu-DOTA-trastuzumab
Gang Niu et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2009)
Micro-SPECT/CT with 111In-DTPA-Pertuzumab Sensitively Detects Trastuzumab-Mediated HER2 Downregulation and Tumor Response in Athymic Mice Bearing MDA-MB-361 Human Breast Cancer Xenografts
Kristin McLarty et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging
Eli C. F. Dijkers et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Positron emission tomography (PET) imaging of neuroblastoma and melanoma with 64Cu-SarAr immunoconjugates
Stephan D. Voss et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody
Weibo Cai et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2007)
Molecular imaging as a tool for personalized and targeted anticancer therapy
K. McLarty et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Synthetic affibody molecules: A novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors
Anna Orlova et al.
CANCER RESEARCH (2007)
Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
Patrick J. Perik et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging
T Olafsen et al.
CANCER RESEARCH (2005)
Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [99mTc]-HYNIC-trastuzumab (Herceptin) Fab fragments
Y Tang et al.
NUCLEAR MEDICINE COMMUNICATIONS (2005)
Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using In-111-trastuzumab (Herceptin) Fab fragments
Y Tang et al.
NUCLEAR MEDICINE AND BIOLOGY (2005)
Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes
CA Boswell et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Preclinical characterisation of 111In-DTPA-trastuzumab
MN Lub-de Hooge et al.
BRITISH JOURNAL OF PHARMACOLOGY (2004)
Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors
PM Smith-Jones et al.
NATURE BIOTECHNOLOGY (2004)
MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue
BE Rogers et al.
BIOCONJUGATE CHEMISTRY (2003)
Share Paper
